Application of combination of GLPG0187 and propranolol in preparation of hemangioma treatment or inhibition drugs

By combining GLPG0187 and propranolol, the proliferation, migration, and tube formation of hemangioma endothelial cells are inhibited, solving the problem of side effects of propranolol monotherapy in infantile hemangiomas and achieving a safer and more effective treatment.

CN122163608APending Publication Date: 2026-06-09NANTONG UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202610322395.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-17
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Current technologies for treating infantile hemangiomas with propranolol have side effects, and the efficacy of monotherapy is limited, failing to effectively inhibit the proliferation, migration, and tube formation of hemangioma endothelial cells.

Method used

The combined use of GLPG0187 and propranolol, with GLPG0187 being an integrin β1 inhibitor and propranolol being a β-receptor blocker, provides a safer and more effective treatment option by inhibiting the proliferation, migration, and tube formation of hemangioma endothelial cells.

Benefits of technology

The combination of GLPG0187 and propranolol significantly enhanced the inhibitory effect on hemangioma endothelial cells, reduced the dosage of propranolol, decreased the risk of side effects, and provided a safer and more effective treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of GLPG0187 combined with propranolol in preparation of a medicine for treating or inhibiting hemangioma. The GLPG0187 is an integrin beta 1 inhibitor, and the propranolol is a beta receptor blocker. Through verification of a CCK8 experiment, a scratch experiment and a tube forming experiment, results show that compared with a propranolol single drug, the combination of GLPG0187 (4 nM) and propranolol (20-30 [mu] M) can further inhibit proliferation, migration and tube forming ability of human hemangioma endothelial cells, and the effect is better than that of the use of the propranolol single drug. Aiming at the problem that about 2.1% of patients have side effects of sleep disorder, bronchospasm, hypoglycemia and the like when single propranolol is used for treating infantile hemangioma in the prior art, the invention provides a new drug combination scheme, and provides a new drug choice for reducing the clinical dosage of propranolol and reducing the occurrence risk of side effects. A new target spot for treating hemangioma is found, and new possibility is provided for hemangioma treatment.
Need to check novelty before this filing date? Find Prior Art